Guía de práctica clínica para la detección oportuna, diagnóstico, tratamiento y seguimiento de linfoma de Hodgkin y linfoma no Hodgkin en niños, niñas y adolescentes

Objectives

Provide an evidence-based Comprehensive Care Guideline for the timely detection, diagnosis, risk stratification, treatment and follow-up of Hodgkin lymphoma and non-Hodgkin lymphoma in children and adolescents in Colombia. The guideline seeks to improve disease-free and overall survival, quality of life and care quality; reduce unjustified variation in specialised management; promote rational resource use; and identify clinical and economic research priorities.[1][2][3][4]It responds to unequal childhood-cancer outcomes, treatment interruption, transfers between institutions, abandonment and fragmented care that can contribute to avoidable mortality.[5][1]

• Standardise integrated paediatric lymphoma care from early detection through survivorship, including risk factors, diagnosis, staging, stage- and subtype-specific treatment, prognostic assessment, follow-up and management of late effects.[6][7][2][8]
• Centralise confirmation, treatment and follow-up in third- or fourth-level institutions with paediatric oncology, paediatric onco-haematology or paediatric haematology expertise.[2][9][4][8]
• Strengthen early recognition and immediate referral through the Integrated Management of Childhood Illnesses early childhood-cancer module, particularly because delayed referral, diagnosis and treatment can worsen survival.[10][11][12][13]
• Apply risk-adapted Hodgkin lymphoma treatment according to anatomical stage, B symptoms, bulky disease, extranodal involvement and treatment response, generally using multi-agent chemotherapy with radiotherapy where indicated while minimising long-term morbidity.[14][15][16][17]
• Apply pathology-confirmed, subtype- and risk-specific non-Hodgkin lymphoma protocols, including BFM-90 or BFM-95 for relevant B-cell and anaplastic large-cell lymphomas and acute lymphoblastic leukaemia-type strategies for lymphoblastic lymphoma.[18][19][20][21][22]
• Ensure continuity of treatment without unjustified interruptions and monitor adherence, relapse, causes of death, treatment-related morbidity and late effects.[23][1][16][24]
• Support long-term survivorship follow-up to identify relapse in the first five years and subsequent second neoplasms, cardiovascular disease, thyroid dysfunction, pulmonary complications and other treatment-related risks.[25][26][27][28]

Implementation

Implementation combines evidence-based clinical pathways, specialised multidisciplinary delivery, national dissemination and institutional adoption. Recommendations were developed de novo for the Colombian context after available guidance was judged insufficiently suitable for adaptation, using systematic evidence reviews, SIGN and GRADE assessment, expert consensus where evidence was limited or contradictory, and consultation with patients, carers and stakeholders.[29][30][31][32][33][34]The Ministry of Health and Social Protection, national and territorial authorities, health institutions, insurers, professional associations, educational institutions and the national technology-assessment body are identified as key implementation actors.[35][36][37]

• Equip primary- and secondary-care personnel to recognise suspected cancer using the Integrated Management of Childhood Illnesses module, stabilise children where necessary, remove administrative barriers and arrange immediate referral without delaying for preliminary investigations.[10][11][12][38][39]
• Deliver care in functional comprehensive paediatric cancer units with resident specialist expertise, trained nursing staff, inpatient and emergency integration, transfusion and pharmacy support, intensive care, pathology, imaging, radiotherapy, rehabilitation, psychosocial, social-work and palliative-care capacity.[40]
• Confirm lymphoma through appropriate tissue sampling, pathology and immunophenotyping, with access to flow cytometry and molecular or genetic testing where indicated; stage disease through relevant imaging, laboratory investigations, bone-marrow examination and cerebrospinal-fluid assessment.[41][42][43][44][45]
• Use positron-emission tomography/computed tomography as the preferred staging and response-assessment modality for Hodgkin lymphoma where available, with computed tomography plus gallium scintigraphy as the specified alternative; confirm positive end-of-treatment lesions by biopsy.[46][47]
• Integrate supportive care by preventing and managing tumour lysis syndrome, monitoring anthracycline-associated cardiac function, providing psychosocial support, and using granulocyte colony-stimulating factors selectively rather than routinely for paediatric non-Hodgkin lymphoma.[48][49][50][51][52][53][54]
• Disseminate and embed the guideline through training, academic curricula, regional multiplier networks, virtual and physical communication channels, institutional implementation leads, quality-assurance mechanisms and adaptation of information systems and electronic health records.[55][35][56][57][58]
• Measure implementation through paediatric oncology information systems, participation in the national paediatric cancer information system and a General Indicator Dashboard covering early-diagnosis-tool use, referral, diagnostic testing, treatment continuity, appropriate protocols and selected preventive therapies.[40][59][60][61]
• Review and update the guideline every three years from the last literature search, refresh evidence, document recommendation changes and propose process and follow-up indicators.[62]

Monitoring & Evaluation

The guideline combines clinical monitoring of paediatric Hodgkin lymphoma and non-Hodgkin lymphoma with implementation monitoring, evidence appraisal and periodic updating. It prioritises timely referral, diagnostic confirmation, treatment continuity, response assessment, relapse detection, late-effects surveillance and institutional adherence to recommended protocols.[1][40][59]

• Monitor overall survival, disease-free or event-free survival, treatment-related morbidity, late effects, causes of death, treatment adherence, abandonment and relapse as core outcomes for standardised paediatric cancer care.[1][23]
• Use paediatric oncology information systems with process, outcome and impact indicators, and connect functional cancer-care units to the national paediatric cancer information system.[40][49]
• Verify and follow treatment adherence within integrated paediatric cancer units, including continuity of protocol-based treatment without unjustified interruptions.[48][40]
• Assess Hodgkin lymphoma response using positron emission tomography/computed tomography after two chemotherapy cycles for early-stage disease and after three cycles for intermediate- or advanced-stage disease.[46]
• Evaluate Hodgkin lymphoma at treatment completion using positron emission tomography/computed tomography after chemotherapy and radiotherapy, confirm positive lesions by biopsy, and perform post-radiotherapy imaging after 8 to 12 weeks.[47]
• Use computed tomography with gallium scintigraphy where positron emission tomography/computed tomography is unavailable for Hodgkin lymphoma staging or response assessment.[46][47]
• Provide specialist Hodgkin lymphoma follow-up to detect relapse during the first five years and late complications, including second neoplasms, cardiovascular disease, thyroid dysfunction and pulmonary complications, thereafter.[28]
• Assess non-Hodgkin lymphoma treatment completion and follow-up through clinical review, blood counts, peripheral-blood film, lactate dehydrogenase, imaging of the primary site, and cerebrospinal-fluid or bone-marrow assessment when clinically indicated.[63][64]
• Monitor methotrexate concentrations when high-dose methotrexate is administered for advanced B-cell non-Hodgkin lymphoma.[19][20]
• Assess tumour lysis syndrome using defined clinical and laboratory criteria, and monitor uric acid, renal complications and mortality in at-risk patients.[65][66]
• Monitor cardiac function in patients receiving anthracyclines or other antineoplastic medicines, while monitoring myelotoxicity during continuous anthracycline infusion.[54]
• Use a General Indicator Dashboard to measure professional adherence and the institutional environment for implementation, including early-detection tool use, referral, diagnostic testing, treatment completion, immunophenotyping and protocol-appropriate treatment.[59][60][61]
• Review and update the guideline every three years from the last literature search, document recommendation changes and propose process and follow-up indicators.[62]

Implementation accountability is distributed across functional care units, institutional implementation leads, national information systems and quality-assurance mechanisms. National bodies and institutional leaders are expected to coordinate, monitor and support adoption, while licensing, accreditation and quality-improvement audits provide wider oversight.[35][67][68]However, many supplied sections do not define indicator targets, baselines, reporting formats, surveillance schedules, audit frequency or formal enforcement arrangements.[62][59][61]

The guideline-development process also includes quality assurance through systematic evidence review, AGREE II appraisal, SIGN and GRADE evidence assessment, RAND or Delphi consensus where evidence is absent or contradictory, patient and caregiver involvement, and publication of stakeholder-feedback analyses.[29][30][32][34][69]

Costing & Financing

Costing information is limited. The guideline development process was financed through Colombia’s Ministry of Social Protection, the Administrative Department of Science, Technology and Innovation, known as COLCIENCIAS, and the National University of Colombia under contract 1609 of 2010; the Ministry of Health and COLCIENCIAS were identified as exclusive financial supporters for preparing, developing and publishing the recommendations.[70][71]

• Use economic evaluation and budget-impact assessment alongside clinical guidance to support government decisions, rational resource use and selection of cost-effective alternatives.[70]
• Apply a health-system-perspective economic evaluation comparing positron emission tomography/computed tomography with computed tomography followed by confirmatory positron emission tomography/computed tomography for end-of-treatment assessment in patients under 18 with Hodgkin lymphoma.[72][73]
• Express the reported economic analysis in 2010 Colombian pesos, using a threshold of three times gross domestic product per capita per life-year gained.[72]
• Recognise that the reported incremental cost per additional life-year gained for positron emission tomography/computed tomography was 2,789,788 Colombian pesos under an assumed 13.4-year life-expectancy difference between true-positive and false-positive cases.[72]
• Identify positron emission tomography/computed tomography as cost-effective when the assumed life-expectancy differential was at least one year.[72]
• Provide institutional research funding of up to 20 monthly legal minimum wages per project through a joint call involving COLCIENCIAS, the Ministry of Health and Social Protection, the Institute for Health Technology Assessment and ICONTEC.[74][57]

Resource and access constraints include lack of coverage for some recommended medicines and procedures, national unavailability of covered procarbazine, non-coverage of specified medicines, costs of imaging and treatment, limited radiotherapy equipment, technology shortages, inadequate hospital capacity, and fragmented insurer-provider arrangements.[75][46][76][77]The supplied material does not provide an overall implementation budget, costed workforce plan, quantified funding gap, resource-mobilisation target or comprehensive economic assumptions beyond the specified diagnostic economic evaluation.[62][36][73]